Allergan (AGN) – Reuters
-
AstraZeneca contacted Gilead over potential megamerger: Bloomberg News
-
Think the S&P 500 is in bad shape? Its components look worse
-
New drugs contribute to AbbVie's upbeat 2020 view; shares hit year-high
-
Dealmakers eye cross-border M&A recovery as mega mergers roll on
-
AbbVie says multiple parties vying for assets related to Allergan deal approval
-
AbbVie 2019 revenue forecast tops Wall Street estimates while it eyes future Botox sales
-
Pfizer to spinoff, merge off-patent drugs unit with Mylan
-
Allergan shareholder Chevedden backs Appaloosa's proposal to split CEO-chairman role
-
Drug companies greet 2019 with U.S. price hikes
-
Pfizer to replace longtime CEO Read with veteran Bourla
-
Allergan says revenue from aesthetics unit may double by 2025
-
U.S. tax cuts prompt rethink by some 'inverted' companies
-
Wall Street rises, investors eye Fed decision, summit fears ebb
-
Two Allergan shareholders call for split of chairman-CEO role
-
Allergan to sell women's health, infectious disease units
-
Pfizer first-quarter results miss estimates as key drug sales fall short
-
Wall Street slides as healthcare drags but manages monthly gain
-
Allergan CEO opposes fundamental shift in strategy, shares fall
-
Oil prices climb after Netanyahu announcement; stocks fall
-
Shire receives new bid from Takeda as takeover deadline looms
-
European shares mark fourth week of gains; Ericsson shines
-
Shire rejects $63 billion Takeda bid as Allergan drops pursuit
-
U.S. patent court deals setback to Allergan's Restasis strategy
-
Allergan completes restructuring, pushes hard in China
-
Allergan to pay Israel's Teva Pharm $700 million to settle dispute
-
New York City sues drug companies over opioid epidemic
-
Exclusive: Ackman cuts staff, shuns limelight as he seeks to turn around fund
-
Allergan to cut over 1,000 jobs as it works to cut costs
-
Pershing Square, Valeant to appear in court on insider trading suit settlement
-
Drugmakers raise 2018 U.S. prices, stick to self-imposed limits
-
Teva Pharm to lay off a quarter of workforce, suspends dividend
-
Allergan to sell a quarter of its Teva stake in first quarter of 2018
-
Pfizer creates chief operating officer role for Bourla
-
U.S. senators press Allergan for details on patent deal with tribe
-
Trump to keep Obama rule curbing corporate tax inversion deals
-
Senators want probe of Allergan transfer deal with tribe: letter
-
Wall St. declines on tech selloff, North Korea concern
-
Drugmaker Teva hires Lundbeck CEO Schultz to restore its health
-
Big-name U.S. hedge funds shed healthcare stocks during the rally in second-quarter
-
Dow chalks up eighth record close in a row
-
Mylan defends chairman to ISS ahead of June 22 investor vote
-
Wall Street mixed after Trump fires FBI head; Nasdaq hits record high
-
Sanofi pegs U.S. drug price rises to below healthcare inflation
-
Allergan posts loss as it writes down Teva holdings
-
NASH: The next untapped pharma market gives investors many options
-
S&P 500 ekes out gain while banks drag on Dow
-
U.S. reaches settlement with Endo on pay-for-delay charges
-
Allergan to pay $15 million over failing to disclose merger talks
-
Wall St. rises, Dow racks up seventh straight weekly gain
-
U.S. states sue Mylan, Teva, others for fixing drug prices
Back to AGN Stock Lookup
